Global Neoantigen Targeted Therapies Market to grow at a CAGR of 8.34%.
Increasing ophthalmic
surgeries and initiatives taken by the government are the major drivers for the
Global Neoantigen Targeted Therapies Market.
According to TechSci Research
report, “Global Neoantigen Targeted Therapies Market Industry Size, Share, Trends, Competition,
Opportunity and Forecast, 2018-2028”, Global Neoantigen Targeted
Therapies Market has valued at USD 1,88 billion in 2022 and is anticipated to
witness an impressive growth in the forecast period with a CAGR of 8.34%
through 2028. This can be ascribed to collaborations and partnerships among leading
companies with a diverse approach to merge the expertise of individual
companies and to strengthen their position in the market.
Awareness and education play
a crucial role in driving the demand for Global Neoantigen Targeted Therapies. Awareness
and education empower patients and their families to actively seek information
about cancer treatments, including emerging therapies like neoantigen-targeted
therapies. Informed patients are more likely to discuss potential treatment
options with their healthcare providers. Education helps patients and
healthcare providers understand the benefits and potential of
neoantigen-targeted therapies. It enables them to make informed decisions about
treatment plans, especially in cases where traditional treatments may have
limitations. Public awareness campaigns and educational initiatives raise
awareness about the prevalence and impact of cancer. They emphasize the
importance of early detection, diagnosis, and the availability of innovative
treatments. Patient awareness about clinical trials, including those involving
neoantigen therapies, encourages participation. Clinical trials are essential
for testing the safety and efficacy of new treatments, and informed patients
are more likely to consider enrolling. Patient advocacy groups and nonprofit
organizations often play a vital role in disseminating information about
neoantigen-targeted therapies. They provide resources, support, and a platform
for patients to share their experiences and knowledge. Educating healthcare
providers, including oncologists and nurses, about neoantigen therapies is
essential. This ensures that they can accurately inform and counsel their
patients regarding treatment options. Increased awareness about cancer symptoms
and risk factors can lead to earlier detection and diagnosis. Neoantigen
therapies are more likely to be effective when used in the earlier stages of
the disease.
Browse over XX market data Figures and spread through 110 Pages and an in-depth TOC on " Global Neoantigen Targeted Therapies Market”
Some
Neoantigen Targeted Therapies use personalized cancer vaccines. These vaccines
contain neoantigens or neoantigen peptides that are administered to the
patient. The immune system is then stimulated to recognize and target cancer
cells bearing these neoantigens. Neoantigen
therapies can be used in combination with checkpoint inhibitors, another type
of immunotherapy. Checkpoint inhibitors release the brakes on the immune
system, allowing it to mount a stronger response against cancer cells,
including those targeted by neoantigens. Patients
undergoing Neoantigen Targeted Therapies are closely monitored to assess their
response to treatment. This may involve regular imaging, blood tests, and other
evaluations to track tumor regression and the durability of the immune
response.
In March 2022, BioNTech SE
has recently announced an expansion of its strategic collaboration with
Regeneron. This expansion aims to advance the development of BNT116, BioNTech's
FixVac candidate, in combination with Libtayo, a PD-1 inhibitor, for the
treatment of advanced non-small cell lung cancer (NSCLC). The collaboration
involves joint clinical trials designed to assess the effectiveness of this
combination therapy in various patient populations with advanced NSCLC. Lung
cancer is one of the most diagnosed malignancies globally and remains a leading
cause of cancer-related mortality. Among lung cancer cases, NSCLC constitutes
approximately 85% of all instances.
According to the agreement, both BioNTech and Regeneron will evenly
split the expenses related to the trials' development. Furthermore, BioNTech
intends to independently initiate and support a Phase 1 clinical trial known as
LuCa-MERIT-1, which will assess the combined use of BNT116 and Libtayo in
additional subpopulations affected by NSCLC.
Resistance and relapse are
a significant challenge in the Global Neoantigen Targeted Therapies Market, as
they are in many cancer treatment approaches. Some patients may not respond to
neoantigen-targeted therapies from the outset. This primary resistance can
occur due to various factors, such as an inadequate immune response, tumour
heterogeneity, or immune evasion mechanisms employed by the cancer cells. Even
when patients initially respond to neoantigen-targeted therapies, resistance
can develop over time. This is known as secondary resistance. Tumour cells can
evolve and adapt to the treatment, making it less effective. Cancer is a
dynamic disease characterized by genetic instability and the continuous evolution
of tumour cells. Over time, cancer cells may acquire new mutations or alter
their neoantigen profile, making them less susceptible to neoantigen-targeted
therapies. Tumour cells can downregulate or lose the expression of the targeted
neoantigens, allowing them to escape immune recognition and attack. This
antigen escape can lead to treatment failure.
Global Neoantigen
Targeted Therapies Market segmentation is based on Target Disease Indication,
Neoantigens Type, Immunotherapy Type, Route of Administration, By Company, and
Region.
Based on Neoantigens
Type, Global Neoantigen Targeted Therapies Market is segmented into Off-the-Shelf
Neoantigens, Personalized Neoantigens. Personalized neoantigens are identified
through genomic sequencing of the patient's tumor. This process involves
analyzing the DNA of the cancer cells to pinpoint the specific genetic
mutations responsible for creating neoantigens. Advanced bioinformatics tools
and algorithms are used to predict and prioritize these mutations. Once the
neoantigens are identified, a personalized treatment approach is developed for
the individual patient. This often involves creating a customized cancer
vaccine or adoptive cell therapy, such as CAR-T cells or TILs (tumor-infiltrating
lymphocytes), designed to target the patient's specific neoantigens. In some
cases, personalized neoantigens are used to create cancer vaccines. These
vaccines contain neoantigens or neoantigen peptides unique to the patient's
tumor. When administered to the patient, the vaccine stimulates the immune
system to recognize and target cancer cells bearing these specific neoantigens.
Another approach involves ACT (Adoptive Cell Therapy), where immune cells,
typically T cells, are harvested from the patient. These T cells are then
genetically modified or expanded in the laboratory to target the identified
neoantigens. The modified T cells are subsequently infused back into the
patient to mount a potent immune response against the cancer cells.
Based on Region, the
North America segment is the dominating segment of Global Neoantigen Targeted
Therapies Market.
North America attracts substantial investment in the biotech and pharmaceutical
sectors. The availability of venture capital, private equity, and public
funding sources provides financial support for research and development
endeavors. North America has a significant population affected by cancer,
including lung cancer, which is a common target for neoantigen therapies. This
large patient population makes it an attractive market for cancer therapies and
clinical trials. The region conducts a substantial number of clinical trials,
including those related to neoantigen-targeted therapies. Clinical trials are
essential for evaluating the safety and efficacy of these treatments. The
region has robust intellectual property protection laws, which encourage
innovation by providing companies with incentives to invest in research and
development. North American researchers and companies often engage in
international collaborations, attracting global talent and expertise to further
advance neoantigen-targeted therapies.
Asia Pacific is the
fastest-growing region in the Global Neoantigen Targeted
Therapies Market. The Asia Pacific region
has witnessed a significant increase in cancer incidence, driven by factors
such as population growth, aging, and lifestyle changes. As cancer rates rise,
there is a growing demand for innovative and effective cancer treatments,
including neoantigen-targeted therapies. Asia Pacific is home to a large and
diverse population, including a significant number of individuals with cancer.
This diverse patient pool provides opportunities for research, clinical trials,
and the adoption of personalized therapies like neoantigen-based treatments. Many
countries in the Asia Pacific region have been increasing their investments in
healthcare infrastructure, research, and development. This has led to greater
access to advanced medical technologies and therapies, including neoantigen-targeted
therapies. The region has seen notable advancements in
genomic sequencing technologies, making it easier and more cost-effective to
identify neoantigens. This has facilitated the development of personalized
cancer treatments.
Some
of the major companies operating in the Global Neoantigen Targeted
Therapies Market include:
- BioNtech SE
- Gritstone Bio, Inc.
- Genocea Biosciences Inc.
- Moderna Inc
- Agenus Inc.
- Immatics NV
- Advaxis Inc
- Precision Biologics
- Gilead Sciences, Inc.
- Cellular Biomedicine Group
Inc.
- Achillies Therapeutics Plc.
- Merck & Co Inc
Download Free Sample Report
Customers can also request 10% free
customization on this report.
“Certain
areas, particularly in North America, are projected to exert significant demand
of Neoantigen Targeted Therapies. The growth in the competitive landscape and
the presence of well-established companies in the market, committed to enhance
the overall wellbeing of people each year, are expected to contribute to a remarkable
growth of the Global Neoantigen Targeted Therapies Market in the forecast
period," said Mr. Karan Chechi, Research Director with TechSci Research, a
research-based Global management consulting firm.
Neoantigen Targeted Therapies Market - Global
Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented by Target Disease Indication (Bone Cancer,
Colorectal Cancer, Gynecological Cancer, Non-Small Cell Lung Cancer, Renal Cell
Carcinoma), By Neoantigens Type (Off-the-Shelf Neoantigens, Personalized
Neoantigens), By Immunotherapy Type (Dendritic Cell Vaccines, DNA / RNA-Based
Vaccines, Protein / Peptide-based Vaccines, TIL-Based Therapies), By Route of
Administration (Intradermal, Intravenous, Subcutaneous), By Region, and
Competition has evaluated the future
growth potential of Global Neoantigen Targeted Therapies Market and provides
statistics & information on market size, structure, and future market
growth. The report intends to provide innovative market intelligence and help
decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Neoantigen Targeted Therapies Market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Web: https://www.techsciresearch.com